Associations between the use of metformin, sulphonylureas, or diet alone and cardiovascular outcomes in 6005 people with type 2 diabetes in the FIELD study

Diabetes Research and Clinical Practice

Volumn 94, Issue 2, 2011, Pages 284-290

  Sullivan, David ^a   Forder, Peta ^b,h   Simes, John ^b   Whiting, Malcolm ^c   Kritharides, Leonard ^d   Merrifield, Alistair ^b,i   Donoghoe, Mark ^b   Colman, Peter G ^e   Graham, Neil ^f   Haapamäki, Hannu ^g   Keech, Anthony ^b  

^a ROYAL PRINCE ALFRED HOSPITAL   (Australia)

^b UNIVERSITY OF SYDNEY   (Australia)

^c FLINDERS MEDICAL CENTRE   (Australia)

^d Centre for Education and Research on Aging   (Australia)

^e ROYAL MELBOURNE HOSPITAL   (Australia)

^f TAURANGA HOSPITAL   (New Zealand)

^g Mehiläinen Lahti ^*  (Finland)

^h UNIVERSITY OF NEWCASTLE   (Australia)

ⁱ UNIVERSITY OF SYDNEY   (Australia)

Author keywords

Cardiovascular disease; Drug interactions; Fenofibrate; Fibrate; Metformin; Sulphonylureas

Indexed keywords

CREATININE; FENOFIBRATE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HOMOCYSTEINE; METFORMIN; PLACEBO; SULFONYLUREA DERIVATIVE;

ADULT; AGE; AGED; ARTICLE; CARDIOVASCULAR DISEASE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIET THERAPY; DISEASE COURSE; DISEASE DURATION; DISEASE SEVERITY; DYSLIPIDEMIA; FEMALE; GENDER; HUMAN; MAJOR CLINICAL STUDY; MALE; MICROANGIOPATHY; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; RISK ASSESSMENT;

ADMINISTRATION, ORAL; AGED; AUSTRALIA; CARDIOVASCULAR DISEASES; CHI-SQUARE DISTRIBUTION; DIABETES MELLITUS, TYPE 2; FEMALE; FENOFIBRATE; HUMANS; HYPOGLYCEMIC AGENTS; HYPOLIPIDEMIC AGENTS; MALE; METFORMIN; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; RISK ASSESSMENT; RISK FACTORS; SULFONYLUREA COMPOUNDS; TIME FACTORS; TREATMENT OUTCOME;

EID: 81255127376     PISSN: 01688227     EISSN: 18728227     Source Type: Journal    
DOI: 10.1016/j.diabres.2011.07.028     Document Type: Article

References (26)

1. Ajjan R.A., Grant P.J. Cardiovascular disease prevention in patients with type 2 diabetes: the role of oral anti-diabetic agents. Diabetes Vasc Dis Res 2006, 3:147-158.
2. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998, 352:837-853. UK Prospective Diabetes Study (UKPDS) Group.
3. Selvin E., Bolen S., Yeh H.-C. Cardiovascular outcomes in trials of oral diabetes medications: a systematic review. Arch Intern Med 2008, 168:2070-2080.
4. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008, 358:2545-2559. Action to Control Cardiovascular Risk in Diabetes Study Group.
5. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008, 358:2560-2572. ADVANCE Collaborative Group.
6. Hoogeveen E.K., Kostense P.J., Jakobs C., Bouter L.M., Heine R.J., Stehouwer C.D. Does metformin increase the serum total homocysteine level in non-insulin-dependent diabetes mellitus?. J Intern Med 1997, 242:389-394.
7. Wierzbicki A.S. Homocysteine and cardiovascular disease: a review of the evidence. Diabetes Vasc Dis Res 2007, 4:143-150.
8. Golstein P., Boom A., van Geffel J., Jacobs P., Masereel B., Beauwen R. P-glycoprotein inhibition by glibenclamide and related compounds. Eur J Physiol 1999, 437:652-660.
9. Van Eck M., Pennings M., Hoekstra M., Out R., Van Berkel T. Scavenger receptor BI and ATP-binding cassette transporter A1 in reverse cholesterol transport and atherosclerosis. Curr Opin Lipidol 2005, 16:307-315.
10. Tamai T., Nakai T., Yamada S., Kobayashi T., Hayashi T., Kutsumi Y., et al. The effects of glibenclamide and insulin on plasma high density lipoproteins in diabetics. Artery 1981, 9:477-493.
11. Calvert G.D., Graham J., Mannik T., Wise P., Yeates R. Effects of therapy on plasma high-density-lipoprotein-cholesterol concentration in diabetes mellitus. Lancet 1978, 2:66-69.
12. Gordon T., Castelli W., Hjortland M., Kannel W., Dawber T. High density lipoprotein as a protective factor against coronary heart disease. Am J Med 1977, 62:707-714.
13. Arakawa R., Tamehiro N., Nishimaki-Mogami T., Ueda K., Yokoyama S. Fenofibric acid, an active form of fenofibrate, increases apolipoprotein A-I-mediated high-density lipoprotein biogenesis by enhancing transcription of ATP-binding cassette transporter A1 gene in a liver X receptor-dependent manner. Arterioscler Thromb Vasc Biol 2005, 25:1193-1197.
14. Dierkes J., Westphal S., Luley C. The effect of fibrates and other lipid-lowering drugs on plasma homocysteine levels. Expert Opin Drug Saf 2004, 3:101-111.
15. Luc G., Jacob N., Bouly M., Fruchart J.C., Staels B., Giral P. Fenofibrate increases homocystinemia through a PPARalpha-mediated mechanism. J Cardiovasc Pharmacol 2004, 43:452-453.
16. Keech A., Simes R.J., Barter P., Best J., Scott R., Taskinen M.R., et al. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet 2005, 366:1849-1861.
17. 2+-polyethylene glycol precipitation, both with enzymatic cholesterol assay compared with the lipid research method. Am J Clin Pathol 1982, 78:718-723.
18. Frick B., Schröcksnadel K., Neurauter G., Wirleitner B., Artner-Dworzak E., Fuchs D. Rapid measurement of total plasma homocysteine by HPLC. Clin Chimica Acta 2003, 331:19-23.
19. Kennedy A., Lappin T., Lavery T., Hadden D., Weaver J., Montgomery D. Relation of high-density lipoprotein cholesterol concentration to type of diabetes and its control. Br Med J 1978, 2:1191-1194.
20. Reaven G. Abnormal lipoprotein metabolism in non-insulin-dependent diabetes mellitus. Pathogenesis and treatment. Am J Med 1987, 83:31-40.
21. Howard B., Xiaoren P., Harper I., Foley J., Cheung M., Taskinen M. Effect of sulfonylurea therapy on plasma lipids and high-density lipoprotein composition in non-insulin-dependent diabetes mellitus. Am J Med 1985, 79:78-85.
22. Simpson S., Majumdar S., Tsuyuki R., Eurich D., Johnson J. Dose-response relation between sulfonylurea drugs and mortality in type 2 diabetes mellitus: a population-based cohort study. CMAJ: Can Med Assoc J 2006, 174:169-174.
23. Kawaki J., Nagashima K., Tanaka J., Miki T., Miyazaki M., Gonoi T., et al. Unresponsiveness to glibenclamide during chronic treatment induced by reduction of ATP-sensitive K+ channel activity. Diabetes 1999, 48:2001-2006.
24. Bertolini S., Pisciotta L., Seri M., Cusano R., Cantafora A., Calabresi L., et al. A point mutation in ABC1 gene in a patient with severe premature coronary heart disease and mild clinical phenotype of Tangier disease. Atherosclerosis 2001, 154:599-605.
25. Wulffelé M.G., Kooy A., de Zeeuw D., Stehouwer C.D., Gansevoort R.T. The effect of metformin on blood pressure, plasma cholesterol and triglycerides in type 2 diabetes mellitus: a systematic review. J Intern Med 2004, 256:1-14.
26. Rao A., Kuhadiya N., Reynolds K., Fonseca V. Is the combination of sulfonylureas and metformin associated with an increased risk of cardiovascular disease or all-cause mortality? A meta-analysis of observational studies. Diabetes Care 2008, 31:1672-1678.